Powder: -20°C for 3 years | In solvent: -80°C for 1 year
α-Glucosidase-IN-16 is a highly effective and orally bioavailable inhibitor of α-glucosidase, displaying a remarkable IC50 value of 3.28 μM. This compound demonstrates the ability to significantly decrease blood glucose levels in diabetic rats induced by Streptozotocin. Notably, α-Glucosidase-IN-16 also exhibits noteworthy antidiabetic activity [1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | α-Glucosidase-IN-16 is a highly effective and orally bioavailable inhibitor of α-glucosidase, displaying a remarkable IC50 value of 3.28 μM. This compound demonstrates the ability to significantly decrease blood glucose levels in diabetic rats induced by Streptozotocin. Notably, α-Glucosidase-IN-16 also exhibits noteworthy antidiabetic activity [1]. |
体内活性 | α-Glucosidase-IN-16 (compound 13B) (10 and 20 mg/kg; PO; once daily for 28 days) significantly reduces the level of blood glucose in diabetic rats [1]. α-Glucosidase-IN-16 (2000 mg/kg; PO; single dosage) exhibits no toxic effects in mice [1]. α-Glucosidase-IN-16 (10 and 20 mg/kg; PO; single dosage) significantly reduces serum glucose level after glucose administration in rats [1]. Animal Model: Wistar rats (170-200 g, 8-10 weeks; induced diabetes by intraperitoneal injection of Streptozotocin ) [1] Dosage: 10 and 20 mg/kg Administration: PO; once daily for 28 days Result: Caused a significant reduction in the level of blood glucose compared to diabetic control. Lowered the total cholesterol level. Effect of α-Glucosidase-IN-16 on blood glucose (mg/dL) in Streptozotocin -induced diabetes [1]. dose (mg/kg) day 1 day 7 day 14 day 21 day 28 10 370.81 ± 4.79 289.89 ± 4.33 200.33 ± 4.57 149.30 ± 4.56 132.98 ± 4.33 20 375.31 ± 5.01 230.71 ± 4.88 163.68 ± 4.37 120.72 ± 4.11 108.42 ± 3.98 Animal Model: Balb/C mice [1] Dosage: 2000 mg/kg Administration: PO; single dosage (acute toxicity study) Result: Exhibited no toxic effects (via observing signs of diarrhea, convulsions, lethargy, sleeping, salivation, and tremor). Animal Model: Wistar rats (oral administration with 3 g/kg glucose) [1] Dosage: 10 and 20 mg/kg Administration: PO; single dosage (oral glucose tolerance test) Result: Significantly reduced serum glucose level (110-113 mg/dL) compared to the control group (128 mg/dL) after 2 hours of glucose administration. |
分子量 | 347.45 |
分子式 | C22H18FNS |
CAS No. | 1606142-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
α-Glucosidase-IN-16 1606142-34-0 Inhibitor inhibitor inhibit